SeQure Dx emerged from stealth mode with tech developed at the hospital and Harvard Medical School, also in Boston, and funding raised in a 2021 $17.5 million series A round.
“Evaluating potential off-target edits created by these therapies plays an enormous role in the advancement of safe and effective gene editing,” said SeQure Dx co-founder Keith Joung, MD, PhD, the endowed chair of pathology at Massachusetts General Hospital, in a Nov. 16 news release from the spinoff. “It’s crucial to define any potential off-target edits from program discovery to eventual patient treatment, and SeQure Dx’s comprehensive assay and data solutions does this using state-of-the-art methods.”
The company’s CEO, director and co-founder, Ellen Sheets, MD, is a former executive-in-residence at Mass General Brigham Ventures, the venture capital arm of the Somerville, Mass.-based health system. That fund participated in the 2021 investment round for SeQure Dx.
